Longitudinal Changes in Serum Glucose Levels are Associated with Metabolic Changes in Alzheimer's Disease Related Brain Regions

Journal of Alzheimer's Disease : JAD
Christine M BurnsEric M Reiman

Abstract

The association between longitudinal changes in serum glucose level and longitudinal changes in [18F] Fluorodeoxyglucose-PET (FDG PET) measurements of Alzheimer's disease (AD) risk are unknown. To investigate whether variation in serum glucose levels across time are associated with changes in FDG PET measurements of cerebral metabolic rate for glucose (rCMRgl) in brain regions preferentially affected by Alzheimer's disease (AD). Participants are a subset of a prospective cohort study investigating FDG PET, apolipoprotein E (APOE) ɛ4, and risk for AD which includes data from baseline, interim, and follow up visits over 4.4±1.0-years. An automated brain-mapping algorithm was utilized to characterize and compare associations between longitudinal changes in serum glucose levels and longitudinal changes in rCMRgl. This study included 80 adults aged 61.5±5 years, including 38 carriers and 42 non-carriers of the APOE ɛ4 allele. Longitudinal increases in serum glucose levels were associated with longitudinal CMRgl decline in the vicinity of parietotemporal, precuneus/posterior cingulate, and prefrontal brain regions preferentially affected by AD (p < 0.05, corrected for multiple comparisons). Findings remained significant when controll...Continue Reading

References

Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Jul 1, 1997·The American Journal of Psychiatry·E M ReimanK Chen
Apr 2, 2003·The American Journal of Psychiatry·Irving I Gottesman, Todd D Gould
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON
Apr 20, 2004·European Journal of Pharmacology·G Stennis Watson, Suzanne Craft
Jun 4, 2005·Proceedings of the National Academy of Sciences of the United States of America·Eric M ReimanJohn Hardy
Aug 19, 2006·Stroke; a Journal of Cerebral Circulation·Vladimir HachinskiGabrielle G Leblanc
Jan 13, 2009·Biochimica Et Biophysica Acta·Jarbas S Roriz-FilhoMatheus Roriz-Cruz
Oct 6, 2011·Journal of Alzheimer's Disease : JAD·Eric M ReimanPierre N Tariot
Apr 24, 2013·Neurobiology of Aging·Madhav ThambisettySusan M Resnick
Aug 9, 2013·The New England Journal of Medicine·Paul K CraneEric B Larson
Aug 14, 2013·Diabetes Care·Chris MoranVelandai Srikanth
Mar 22, 2014·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Rosebud O RobertsVal J Lowe
Jul 22, 2014·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Auriel A WilletteBarbara B Bendlin
Jun 11, 2015·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Kenji IshibashiKenji Ishii
Jun 19, 2016·Neurobiology of Aging·Jill K MorrisJeffrey M Burns

❮ Previous
Next ❯

Citations

Feb 9, 2021·Journal of Alzheimer's Disease : JAD·Jing ZhouPaul K Crane
Apr 6, 2021·Journal of Alzheimer's Disease : JAD·Anna K EdlundHenrietta M Nielsen

❮ Previous
Next ❯

Software Mentioned

SPM8
SPM

Related Concepts

Related Feeds

Alzheimer's Disease: APOE

Apolipoprotein E (APOE) polymorphic alleles are major genetic risk factors for Alzheimer's disease. Discover the latest research on APOE and other genetic determinants of Alzheimer's disease here.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.